Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT04746924
- BEIGENE, BGB-A317-A1217-302, TIGIT-302, CT1363, BGB-302
Commercial Sponsor
BeiGene Australia Pty Ltd
Scientific Title
A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer